专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明申请

US20200237861A1 METHODS OF DIAGNOSING AND TREATING VASCULAR ASSOCIATED MACULOPATHY AND SYMPTOMS THEREOF 审中-公开
公开(公告)号：US20200237861A1
公开(公告)日：2020-07-30
申请号：US16703745
申请日：2019-12-04
申请人： UNIVERSITY OF UTAH RESEARCH FOUNDATION
发明人： Gregory S. Hageman , Giuliana Silvestri , Paulina Haas , Monika Fleckenstein , Christian Matthew Pappas , Robin Guymer
IPC分类号： A61K38/17 , A61K38/08 , A61K38/07 , A61K38/06 , A61K38/00 , A61K31/4422 , A61K31/225 , A61K31/015 , C12Q1/6883
摘要： Disclosed herein are methods and compositions for the diagnosis and treatment of Vascular Associated Maculopathy, or a symptom thereof, in a subject. Disclosed herein are methods and compositions for the diagnosis and treatment of one or more symptoms associated with Vascular Associated Maculopathy Disclosed in a subject. Disclosed herein are methods and compositions for the diagnosis and treatment of severe maculopathy or last stage maculopathy in a subject. Disclosed herein are methods and compositions for the diagnosis and treatment of resolving aberrant choriocapillaris lobules in a subject.

32. 发明授权

US10660789B2 1,4-dihydropyridine derivatives with HSP modulating activity 有权
公开(公告)号：US10660789B2
公开(公告)日：2020-05-26
申请号：US16288833
申请日：2019-02-28
申请人： Richter Gedeon NYRT.
发明人： Ferenc Fülöp , László Vígh , Zsolt Török , Botond Penke , Ibolya Horváth , Gábor Balogh , Sándor Bernáth , Ákos Hunya
IPC分类号： A61K31/4422 , A61K31/443 , A61K31/4436 , C07D211/86 , C07D405/04 , C07D409/04 , A61F7/00 , C07D401/06 , C07D401/10 , C07D211/90 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/475 , A61K31/496 , A61K31/5377 , A61K31/55 , C07D401/14
摘要： The invention provides 1,4-dihydropyridine derivatives of formula (I) wherein R1 is optionally substituted C6-24aryl group or 5 to 6 membered heteroaryl group comprising 1 to 3 nitrogen atoms or other heteroatoms like oxygen and sulphur, and combinations thereof; R2 and R3 are independently hydrogen or C1-6alkyl group; R4 and R5 are independently hydrogen, C1-6alkyl group optionally substituted with amino, mono- or di(C1-6alkyl)amino, or with 5 to 24 membered optionally fused heterocyclic ring attached by nitrogen and optionally comprising additional 1 to 3 N, O, S heteroatoms and optionally substituted with C1-6alkyl group or C1-6 alkoxy group; R6 is C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkylC1-6alkyl or arylC1-6alkyl group; and stereoisomers including enantiomers, diastereomers, racemic mixtures, mixture of enantiomers and combination thereof, as well as polymorphs, pharmaceutically acceptable salts, solvates, esters and prodrugs thereof for use in the therapeutic or prophylactic treatment of a disorder mediated by heat shock proteins.

33. 发明申请

US20200155529A1 METHODS FOR TREATING CARPAL TUNNEL PAIN 审中-公开
公开(公告)号：US20200155529A1
公开(公告)日：2020-05-21
申请号：US16742482
申请日：2020-01-14
申请人： David WISE
发明人： David WISE
IPC分类号： A61K31/4422 , A61M29/00 , A61K9/00 , A61K9/02 , A61K31/573 , A61K31/198 , A61K31/167 , A61K45/06 , A61K31/554
摘要： Methods are provided for treating conditions including chronic pelvic pain, in which there are palpable trigger points of local areas of muscle restriction and spasticity that recreate or refer pain of patients complaints upon palpation, chronic pelvic pain syndrome, pelvic floor myalgia, pelvic floor dysfunction, interstitial cystitis, levator ani syndrome, coccygodynia, prostatodynia, piriformis syndrome, anal sphincter pain, bowel movement pain, post bowel movement pain, ejaculatory pain, post ejaculatory pain, sitting pain, post bowel movement pain, rectal pain, tailbone pain, urinary frequency, urinary urgency, urinary hesitancy, post urinary pain, overactive bladder, perineal pain, penile pain, vaginismus, anismus, sexual dysfunction, reduced level of ejaculate or reduced penile erection, myofascial pain in muscle tissue of a patient who has one or more trigger points in the muscle tissue, or the pain/sensitivity of pelvic floor muscle trigger points and specific areas of myofascial restriction detected upon palpation in a patient comprising administering to the one or more trigger points of the patient in need thereof a therapeutically effective amount of a calcium channel blocker, or L-arginine, or a combination of a calcium channel blocker and L-arginine, or pharmaceutically acceptable salts, hydrates, solvates and prodrugs thereof; the application of the topical form of the drug can be applied by the patient regularly as part of a self treatment program to heal muscle related pain and muscle related pelvic pain and each optionally together with a corticosteroid such as cortisone of hydrocortisone. The invention further provides methods for myofascial release, trigger point release, and the use of dilators with and without calcium channel blockers for pain conditions. The invention further provides pharmaceutical compositions, kits and applicator devices useful in the methods of the invention.

34. 发明授权

US10576070B2 Non-aqueous liquid nimodipine compositions 有权
公开(公告)号：US10576070B2
公开(公告)日：2020-03-03
申请号：US16407980
申请日：2019-05-09
申请人： ARBOR PHARMACEUTICALS, LLC
发明人： Hugh Greg Thomas
IPC分类号： A61K31/4422 , A61K47/10 , A61K9/08 , A61P25/00
摘要： Non-aqueous liquid compositions comprising nimodipine having improved stability over aqueous compositions comprising nimodipine are provided herein. Methods of improving neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms with the non-aqueous liquid compositions of the present invention are also detailed herein.

35. 发明授权

US10555955B2 Trimegestone (TMG) for treatment of preterm birth 有权
公开(公告)号：US10555955B2
公开(公告)日：2020-02-11
申请号：US15706444
申请日：2017-09-15
申请人： DIGNITY HEALTH
发明人： Robert E. Garfield , Shao-Qing Shi , Leili Shi
IPC分类号： A61K31/575 , A61K9/00 , A61K31/4418 , A61K31/405 , A61K31/4422 , A61K33/06 , A61K45/06 , A61K47/44 , A61K38/095
摘要： As disclosed herein, novel compositions including steroid hormones, such as trimegestone (TMG) and progesterone (P4), provide treatments for term and preterm labor with significant effects on the delay of delivery. Delay and block of delivery occurs when both P4 and TMG are administered late in gestation in pregnant rat and guinea pig animal models. TMG exhibits remarkable drug efficacy, achieving the same inhibition as P4, but at much lower doses. These hereto unknown effects of TMG on the processes of cervical ripening and uterine contraction provide a novel approach for extending pregnancy term, including reducing a likelihood of preterm and/or term labor, along with improved methods of administration. Other diseases and/or conditions may be treated with TMG, such as dysmenorrhea or luteal insufficiency for sustaining pregnancy.

36. 发明授权

US10543201B2 Compositions and methods for treating pelvic pain and other conditions 有权
公开(公告)号：US10543201B2
公开(公告)日：2020-01-28
申请号：US15644053
申请日：2017-07-07
申请人： David Wise
发明人： David Wise
IPC分类号： A61K31/4422 , A61K31/554 , A61K45/06 , A61K31/167 , A61K31/198 , A61K31/573 , A61K9/02 , A61K9/00 , A61M29/00 , A61K47/14 , A61K9/06 , A61K47/44 , A61K47/10
摘要： Methods are provided for treating conditions including chronic pelvic pain, in which there are palpable trigger points of local areas of muscle restriction and spasticity that recreate or refer pain of patients complaints upon palpation, chronic pelvic pain syndrome, pelvic floor myalgia, pelvic floor dysfunction, interstitial cystitis, levator ani syndrome, coccygodynia, prostatodynia, piriformis syndrome, anal sphincter pain, bowel movement pain, post bowel movement pain, ejaculatory pain, post ejaculatory pain, sitting pain, post bowel movement pain, rectal pain, tailbone pain, urinary frequency, urinary urgency, urinary hesitancy, post urinary pain, overactive bladder, perineal pain, penile pain, vaginismus, anismus, sexual dysfunction, reduced level of ejaculate or reduced penile erection, myofascial pain in muscle tissue of a patient who has one or more trigger points in the muscle tissue, or the pain/sensitivity of pelvic floor muscle trigger points and specific areas of myofascial restriction detected upon palpation in a patient comprising administering to the one or more trigger points of the patient in need thereof a therapeutically effective amount of a calcium channel blocker, or L-arginine, or a combination of a calcium channel blocker and L-arginine, or pharmaceutically acceptable salts, hydrates, solvates and prodrugs thereof; the application of the topical form of the drug can be applied by the patient regularly as part of a self treatment program to heal muscle related pain and muscle related pelvic pain and each optionally together with a corticosteroid such as cortisone of hydrocortisone. The invention further provides methods for myofascial release, trigger point release, and the use of dilators with and without calcium channel blockers for pain conditions. The invention further provides pharmaceutical compositions, kits and applicator devices useful in the methods of the invention.

37. 发明授权

US10513518B2 Inhibitors of the renal outer medullary potassium channel 有权
公开(公告)号：US10513518B2
公开(公告)日：2019-12-24
申请号：US15544295
申请日：2016-01-25
申请人： Merck Sharp & Dohme Corp.
发明人： Reynalda K. deJesus , Qinghong Fu , Jinlong Jiang , Haifeng Tang
IPC分类号： A61K31/435 , A61K31/55 , A61K31/5386 , A61K31/424 , C07D471/10 , C07D487/10 , C07D498/10 , A61K31/401 , A61K31/41 , A61K31/4178 , A61K31/4184 , A61K31/439 , A61K31/4422 , A61K31/4523 , A61K31/5377 , C07D471/20 , A61K31/444 , A61K31/46 , A61K45/06 , C07D451/00
摘要： The present invention provides compounds of Formula I (I) and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

38. 发明申请

US20190385709A1 METHODS FOR LOWERING BLOOD PRESSURE WITH A DIHYDROPYRIDINE-TYPE CALCIUM CHANNEL BLOCKER PHARMACEUTICAL COMPOSITION 审中-公开
公开(公告)号：US20190385709A1
公开(公告)日：2019-12-19
申请号：US16440319
申请日：2019-06-13
申请人： AstraZeneca UK Limited
发明人： Richard L. Skelly , Judy Firor
IPC分类号： G16H10/20 , G16H10/40 , G16H10/60 , G16H20/10 , G16H70/40 , A61K31/4422
摘要： A method is provided for lowering blood pressure in a subject in need thereof by administering a dihydropyridine-type calcium channel blocker pharmaceutical composition to a subject qualified for over-the-counter access to the dihydropyridine-type calcium channel blocker pharmaceutical composition. In some embodiments, the dihydropyridine-type calcium channel blocker pharmaceutical composition includes isradipine, nifedipine, or nisoldipine. In some embodiments, the dihydropyridine-type calcium channel blocker pharmaceutical composition includes 3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate or a pharmaceutically acceptable salt thereof.

39. 发明申请

US20190321388A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR POTENTIATING GENE SILENCING 审中-公开
公开(公告)号：US20190321388A1
公开(公告)日：2019-10-24
申请号：US16313754
申请日：2017-06-29
申请人： OliX Pharmaceuticals, Inc.
发明人： Dong Ki LEE , Da Seul SON , Yang Hee KIM
IPC分类号： A61K31/713 , C12N15/113 , A61K31/277 , A61K31/554 , A61K31/137 , A61K31/4439 , A61K31/444 , A61K31/665 , A61K31/497 , A61K31/4422
摘要： In various aspects and embodiments, the invention provides compounds or agents that potentiate siRNA cellular entry or activity, and provides methods for identifying such compounds or agents. Exemplary agents that act as L-type calcium channel blockers are described herein, and are shown to potentiate gene silencing with cp-asiRNAs.

40. 发明申请

US20190321358A1 ABUSE-PROOFED DOSAGE FORM 审中-公开
公开(公告)号：US20190321358A1
公开(公告)日：2019-10-24
申请号：US16455813
申请日：2019-06-28
申请人： GRÜNENTHAL GMBH
发明人： Elisabeth ARKENAU-MARIC , Johannes BARTHOLOMAEUS , Heinrich KUGELMANN
IPC分类号： A61K31/485 , B29C48/00 , A61K9/20 , B29C48/21 , B29C48/14 , A61K31/55 , B29C43/02 , A61K9/48 , A61J3/00 , A61K31/135 , A61K31/554 , A61K31/4418 , B29B7/00 , A61K31/277 , B29B9/02 , A61J3/06 , A61K31/4422 , A61J3/10 , B29B9/12 , A61K9/28
摘要： The invention relates to a dosage form that is thermoformed without discoloration and is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse. The invention also relates to a corresponding method for producing said dosage form.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式